AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2658396
Drug: telenzepine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telenzepine 3 mg once-daily at bedtime
Trial: 2658396
Drug: pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pirenzepine 50 mg two times daily
Trial: 31678098
Drug: LOR-mod (moderate-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOR-mod (moderate-dose Lorexys)
Trial: 31678098
Drug: BUP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP (standard dose bupropion)
Trial: 31678098
Drug: LOR-low (subtherapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOR-low (subtherapeutic dose Lorexys)
Trial: 20965577
Drug: RTL1000 (≤60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTL1000 (≤60 mg)
Trial: 13680036
Drug: L‐NMMA 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 0.3 mg/kg iv
Trial: 13680036
Drug: L‐NMMA 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 1 mg/kg iv
Trial: 13680036
Drug: L‐NMMA 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 3 mg/kg iv
Trial: 13680036
Drug: L‐NMMA 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 6 mg/kg iv
Trial: 10900778
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Support (school-based anti-bullying intervention with additional support)
Trial: 10900778
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without Support (school-based anti-bullying programme without additional support)
Trial: 8737127
Drug: Comparator antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin, or amoxycillin)
Trial: 1570234
Drug: Low-dose Troleandomycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Troleandomycin (TAO) therapy
Trial: 24949654
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin glulisine initiated at a fifth (20%) the dose of insulin glargine
Trial: 24949654
Drug: Maximized dose
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximized dose of sitagliptin to 100 mg
Trial: 23185923
Drug: Intrathecal neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal neostigmine 25 microg combined with 0.5% hyperbaric bupivacaine 15 mg and fentanyl 25 microg
Trial: 23185923
Drug: Saline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.5 ml) combined with 0.5% hyperbaric bupivacaine 15 mg and fentanyl 25 microg
Trial: 15923431
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen (Irinotecan 180 mg/m² on day 1 with LV5FU2 regimen)
Trial: 10832123
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (rt-PA 50 mg, 10 mg as a bolus plus 40 mg in 60 min)
Trial: 10832123
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (conventional therapy)
Trial: 1639462
Drug: captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril (25 mg b.i.d.) for 4 days
Trial: 6436868
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 1 g
Trial: 6436868
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 2 g
Trial: 6436868
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 4 g
Trial: 6436868
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg (Control)
Trial: 11736725
Drug: Ulcer healing
RxNorm normalized name: Ulcer healing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulcer healing treatment followed by maintenance therapy
Trial: 7909049
Drug: Oral slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow-release theophylline, 200 mg 12 hourly
Trial: 28042649
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (selenomethionine 83 mcg/day for four months)
Trial: 16849403
Drug: NBI-42902 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI-42902 (5 mg)
Trial: 16849403
Drug: NBI-42902 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI-42902 (150 mg)
Trial: 12570823
Drug: Leukocytapheresis (LCAP)
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytapheresis (LCAP) weekly for 5 weeks, then once every 4 weeks as maintenance therapy
Trial: 12570823
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose prednisolone (h-PSL) 30-40 mg/day for moderately severe and 60-80 mg/day for severe patients, then gradually tapered
Trial: 9090733
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment only
Trial: 8477962
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (13 to 15 mg daily)
Trial: 28621011
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (8 weekly 75-min classes)
Trial: 12559536
Drug: Amiodarone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone and verapamil 240 mg/day (group VER)
Trial: 12559536
Drug: Amiodarone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone and metoprolol 100 mg/day (group MET)
Trial: 9083316
Drug: Intravaginal misoprostol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol, 50 microg every 4 hours up to three doses (n = 76)
Trial: 9083316
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone gel, 0.5 mg every 6 hours up to three doses (n = 79)
Trial: 8472213
Drug: He:Ne laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: He:Ne laser treatment
Trial: 8472213
Drug: He:Ne +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: He:Ne + Nd:YAG laser treatment
Trial: 16546596
Drug: Naltrexone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone administration
Trial: 27753111
Drug: HyCoSy (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HyCoSy (saline solution)
Trial: 26324322
Drug: Stabilization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilization treatment
Trial: 25452017
Drug: Movement system
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement system impairment-based treatment
Trial: 21493422
Drug: Pillar implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pillar implants
Trial: 9296429
Drug: Topical 60%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 60% lidocaine tape (Group B)
Trial: 9296429
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine mixed with propofol (Group C)
Trial: 19926008
Drug: Amlodipine, Lisinopril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine, Lisinopril, Doxazosin
Trial: 14719298
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment using the eight methods of intelligent turtle (Ling Gui Ba Fa)
Trial: 10802401
Drug: Alora placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alora placebo patch
Trial: 12621596
Drug: Flumazenil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (2 mg)
Trial: 2000035
Drug: 250 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/kg body weight (BW) protein meal
Trial: 2000035
Drug: 500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg BW protein meal
Trial: 2000035
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg BW protein meal
Trial: 2000035
Drug: 2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/kg BW protein meal
Trial: 2000035
Drug: 250 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/kg BW protein meal
Trial: 27111273
Drug: Partially hydrolysed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHF‐OS)
Trial: 18062596
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (prolonged conservative treatment with later surgery if necessary)
Trial: 16130059
Drug: Ketamine anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine anesthesia (IV ketamine 1 to 2 mg/kg, fentanyl 1 to 2 microg/kg, maintained with ketamine 25 to 75 microg/kg/min and fentanyl 10 microg/kg/h)
Trial: 16130059
Drug: Isoflurane anesthesia
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane anesthesia (IV thiopental sodium 3 to 5 mg/kg, fentanyl 1 to 2 microg/kg, maintained with 1% isoflurane and fentanyl 10 microg/kg/h)
Trial: 8757425
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 1,000 mg alone
Trial: 8757425
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 500 mg + low-dose interferon-alpha (IFN-alpha 3 MIU three times weekly)
Trial: 30703349
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (ESI) and education only
Trial: 30703349
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection plus physical therapy (ESI+PT)
Trial: 26460229
Drug: 24-weeks group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-weeks group (discontinuation of risperidone or olanzapine at 24 weeks)
Trial: 24436491
Drug: Renal-specific oral
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal-specific oral nutrition supplement (RS-ONS)
Trial: 22952598
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) 8 g/d (1.6 g/d EPA+DHA)
Trial: 22952598
Drug: High oleic
RxNorm normalized name: High Oleic Sunflower Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oleic sunflower oil (HOSO) 8 g/d
Trial: 19544043
Drug: Splinting plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splinting plus low-level laser therapy (SLLLT)
Trial: 17894323
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of ribavirin (RBV)
Trial: 17894323
Drug: Flat dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat dosing of ribavirin (RBV)
Trial: 11132612
Drug: Sildenafil (25-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25-200 mg)
Trial: 9113185
Drug: ALAGLN-group (alanyl-glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALAGLN-group (alanyl-glutamine solution)
Trial: 9113185
Drug: AA-group (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA-group (glucose and balanced amino acid solution)
Trial: 9493699
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 mg
Trial: 9493699
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 mg
Trial: 27474536
Drug: Single solar‐simulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single solar‐simulated UVR exposure of 3 Standard Erythema Dose at 30 minutes or 24 hours after IPL
Trial: 21988742
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-esterase inhibitor (200 U/kg intravenously)
Trial: 16503705
Drug: Stepwise methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise methadone induction (28, 56, then 84 mg/day)
Trial: 16503705
Drug: Rapid methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid methadone induction (28-84 mg on Days 1-6 to 56 mg/day)
Trial: 12905979
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (PPI + bismuth-based triple therapy)
Trial: 12905979
Drug: PPI-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based triple therapy
Trial: 3920861
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Sorbinil
Trial: 3920064
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Sorbinil
Trial: 3920064
Drug: Topical 0.5
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5 mg ophthalmic Sorbinil
Trial: 3920064
Drug: Oral Sorbinil
RxNorm normalized name: sorbitol Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Sorbinil
Trial: 3920064
Drug: Topical ophthalmic
RxNorm normalized name: MIOTICS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic preparation
Trial: 20617660
Drug: Voluntary management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary management breathing control therapy
Trial: 10632415
Drug: Transdermal 17beta‐E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐E2 (50 microg/d)
Trial: 10632415
Drug: Transdermal 17beta‐E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐E2 (50 microg/d) + norethisterone acetate (250 microg/d)
Trial: 8795747
Drug: Glaucoma treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glaucoma treatment interventions (specifics not provided)
Trial: 8795747
Drug: Controlled trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled trials of glaucoma treatments (specifics not provided)
Trial: 26603250
Drug: Cognitive‐behavioural therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioural therapy (CBT)
Trial: 18234488
Drug: 800 mg/d
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/d of imatinib (400mg BID)
Trial: 18234488
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d of imatinib
Trial: 10100554
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CY) 3 g/m2
Trial: 10100554
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CY) 4 g/m2
Trial: 10100554
Drug: Prior chemotherapy
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior chemotherapy regimen (1 regimen)
Trial: 10100554
Drug: Prior chemotherapy
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior chemotherapy regimen (>=2 regimens)
Trial: 8947399
Drug: Hamstring tendons-ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hamstring tendons-ligament augmentation device anterior cruciate ligament reconstructions
Trial: 1768562
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of indocyanine green (ICG) at 1.0 mg min‐1 for 150 min
Trial: 1768562
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol (10 mg in 10 min)
Trial: 1768562
Drug: Three 1-min
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 1-min infusions of ICG (0.5 mg kg‐1) administered at corresponding times of the day
Trial: 27605086
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of beta-carotene and vitamin C supplements
Trial: 25908099
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg by intravenous bolus injection
Trial: 19176949
Drug: Antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic lock solution of gentamicin (4 mg/ml) heparin (G group)
Trial: 19176949
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (H group)
Trial: 11493411
Drug: Atovaquone (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone (1,000 mg) and proguanil hydrochloride (400 mg) daily for 3 days
Trial: 11493411
Drug: Chloroquine (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (1,500 mg over 3 days)
Trial: 11493411
Drug: Pyrimethamine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (75 mg) and sulfadoxine (1,500 mg) as a single dose
Trial: 9715425
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg) plus amoxycillin (500 mg) twice daily for 2 weeks (LA-60 group)
Trial: 9715425
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily) plus amoxycillin (500 mg twice daily for 2 weeks (LA-30 group)
Trial: 9715425
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily for 6 or 8 weeks (LPZ group)
Trial: 2375945
Drug: Caffeine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine, 10 mg/kg
Trial: 385096
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (500 mg b.d.) for 7 days before operation
Trial: 31915996
Drug: Enoxaparin-warfarin (enox-warfarin)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin-warfarin (enox-warfarin)
Trial: 25819354
Drug: ossein-hydroxyapatite complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ossein-hydroxyapatite complex (OHC) 1,660 mg/day
Trial: 25819354
Drug: calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium carbonate (CC) 1,200 mg/day
Trial: 25819354
Drug: calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium carbonate (CC)
Trial: 24786946
Drug: Build Better
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Build Better Bones With Exercise (B3E) intervention including exercise and behavioral counseling, delivered by a physical therapist in 6 home visits over 8 months, and monthly calls; participants are to exercise ≥3 times weekly.
Trial: 8600188
Drug: Sorbitol gum
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol gum (9.0 g/day)
Trial: 2469708
Drug: cetirizine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine, 20 mg
Trial: 1096218
Drug: Haloperidol (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (9 mg/day)
Trial: 1096218
Drug: Clozapine (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (225 mg/day)
Trial: 26303014
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course concurrent palliative chemotherapy (cisplatin at 6mg/m2/day IV bolus for 5 days) plus radiotherapy (RT as arm A)
Trial: 21504334
Drug: Sitagliptin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin administration alone or with a concomitant drug
Trial: 8186781
Drug: Intravenous alfentanil-midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanil-midazolam anesthesia
Trial: 2660754
Drug: Aztreonam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (1 gr. IM daily for 7 days)
Trial: 30953731
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (waitlist control)
Trial: 19749496
Drug: Other statins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other statins (Simvastatin 40 mg/day, Pravastatin 40 mg/day)
Trial: 16802360
Drug: Calcium (1,000
RxNorm normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1,000 mg) and vitamin D (400 IU) supplementation